| Literature DB >> 26876365 |
Takaaki Furusawa1, Hidetomo Iwano, Hidetoshi Higuchi, Hiroshi Yokota, Masaru Usui, Tomohito Iwasaki, Yutaka Tamura.
Abstract
Pseudomonas aeruginosa is a pathogen frequently identified as the cause of diverse infections or chronic disease. This microbe has natural resistance to several kinds of antibiotics, because of the species' outer membrane, efflux pumps and growth as a biofilm. This bacterium can acquire increased resistance with specific point mutations. Bacteriophage (phage), however, can lyse these bacteria. Therefore, in the present study, we assessed the host range of phages isolates and their ability to lyse antibiotic-resistant P. aeruginosa. Present phages could lyse many strains of P. aeruginosa (28/39), including strains with high resistance to fluoroquinolones (4/6). In conclusion, application of phages for antibiotic-resistant bacteria is greatly effective. To avoid pervasive antibiotic-resistant bacteria, further development of phage usage for disease treatment is required.Entities:
Mesh:
Year: 2016 PMID: 26876365 PMCID: PMC4937139 DOI: 10.1292/jvms.15-0310
Source DB: PubMed Journal: J Vet Med Sci ISSN: 0916-7250 Impact factor: 1.267
Fig. 1.Morphology of phages: electron microscopy. Bar: 100 nm. (A) ΦS12-1: myoviridae. (B) ΦR18: podoviridae. ΦS12-1 has an isometrically hexagonal head, 91.7 ± 0.8 nm in diameter and a contractile tail of 154.2 ± 0.8 nm in length (n=3). ΦR18 has an isometrically hexagonal head, 91.7 ± 0.8 nm in diameter, and a short tail of 78.5 ± 1.5 nm in diameter and 29.8 ± 1.6 nm in length (n=10).
Phage specificity against P. aeruginosa isolated from dog disease
| Bacterial strains | MIC | Phage | ||
|---|---|---|---|---|
| ERFX ( | OBFX ( | ΦS12-1 | ΦR18 | |
| Pa1 | 1 | 4 | C | N |
| Pa4 | 1 | 4 | T | C |
| Pa7 | 1 | 4 | C | N |
| Pa8 | 1 | 4 | N | N |
| Pa11 | 2 | 8 | C | F |
| Pa12 | 2 | 8 | C | C |
| Pa14 | 1 | 4 | C | C |
| Pa16 | 4 | 16 | N | N |
| Pa17 | >128 | >128 | N | N |
| Pa18 | 0.5 | 2 | N | C |
| Pa22 | >128 | >128 | N | N |
| Pa25 | 4 | 16 | T | F |
| Pa26 | 4 | 16 | N | F |
| Pa27 | 4 | 32 | T | T |
| Pa29 | 2 | 8 | N | N |
| Pa34 | 8 | 16 | N | N |
| Pa38 | 1 | 4 | N | N |
| Pa42 | 2 | 4 | C | F |
| Pa43 | 8 | 32 | T | N |
| Pa44 | 0.5 | 2 | N | N |
| Pa49 | 8 | >128 | N | F |
| Pa50 | 8 | >128 | N | T |
| Pa51 | 1 | 4 | C | N |
| Pa52 | 2 | 8 | N | T |
| Pa53 | >128 | >128 | N | T |
| Pa54 | 2 | 8 | T | C |
| Pa56 | 2 | 8 | C | F |
| Pa57 | 2 | 8 | C | N |
| Pa58 | 2 | 2 | N | C |
| Pa59 | 0.5 | 4 | T | N |
| Pa60 | >128 | >128 | N | C |
| Pa61 | >128 | >128 | C | C |
| Pa63 | >128 | >128 | N | C |
| Pa64 | 0.5 | 2 | C | T |
| Pa65 | N | T | ||
| Pa66 | 4 | 8 | F | C |
| Pa67 | 0.5 | 8 | T | N |
| Pa68 | 0.5 | 2 | F | N |
| Pa70 | N | C | ||
Clear spot (C) indicates the highest lysis activity, followed by turbid spot (T), faint spot (F) and no spot (N). Abbreviations: MIC, minimum inhibitory concentration; ORFX, orbifloxacin; ERFX, enrofloxacin.